Pharma Giant Signs Deal to Manufacture Drugs in Orbit, Marking First Commercial Space Manufacturing Pact

By

A startup aiming to produce pharmaceuticals in outer space has secured its first major commercial partner, signaling a milestone for orbital manufacturing. Varda Space Industries announced it has signed United Therapeutics to launch drugs into microgravity to form novel crystal structures.

The agreement represents what Varda calls 'the first commercial path to products made in space,' according to Michael Reilly, the company's chief strategy officer. United Therapeutics CEO Martine Rothblatt, a satellite veteran, said orbital conditions could yield 'even more amazing' versions of existing medicines.

Background

Previously, small-scale experiments on the International Space Station tested how weightlessness affects chemical mixtures—water becomes a wobbly sphere when gravity is absent. Now, Varda plans to send United Therapeutics' drugs into orbit so they can crystallize under microgravity, potentially creating atomic arrangements impossible on Earth.

Varda, based in El Segundo, California, was founded in 2021 by Delian Asparouhov and former SpaceX engineer Will Bruey. The company bets that falling launch costs and frequent rocket flights will make it profitable to ship raw materials into space, process them, and return the finished products to Earth.

What This Means

Pharmaceutical companies often reformulate blockbuster drugs to extend patent protection—switching from pills to inhalers, for example. United Therapeutics has used this strategy for lung disease drugs. Now Varda positions itself as a reformulation partner using orbital facilities instead of terrestrial technologies like nebulizers or nanoparticles.

If successful, this partnership could open a new frontier for drug development. The hope is that microgravity crystals exhibit superior stability or other valuable properties, yielding 'improved versions' that keep imitators at bay. However, the concept remains unproven at commercial scale.

This is a breaking news story. Updates will follow as more details emerge.

Related Articles

• Apple’s Expanding Role in Formula 1: Movie Sequels, Streaming Deals, and a Racing-Driven Engineer
• A New Approach to Gum Disease Prevention: Interrupting Bacterial Communication Without Harming Good Bacteria
• Deadly Free-Living Amoebae on the Rise: Climate Change and Aging Infrastructure Fuel Global Spread
• Cigna to Withdraw from ACA Individual Marketplaces by 2027, Signaling Industry Shifts
• Immunotherapy Before Surgery Wipes Out Colon Cancer for Years, Landmark Trial Shows
• Apple Deepens F1 Ties: Streaming Rights, Movie Sequel, and John Ternus’s Racing Passion
• Stem Cell Therapy Breakthrough Targets Age-Related Blindness in Landmark Trial
• Navigating Biotech Partnerships and Drug Launch Challenges: A Case Study on Capricor's Duchenne Therapy